Evidence From Old Tumors Foretells Which New Breast Cancer Patients Will RequireAdditional Treatment

July 01, 1998

A rare medical archive -- which combines preserved breast cancer tissues with long-term follow-up information on each patient -- has enabled researchers from the University of Chicago Medical Center to determine how precisely two tumor characteristics can predict which breast cancers are likely to spread. They found that patients whose tumors had high levels of the product of a gene family called nm23 (for non-metastasis) and low density of newly formed blood vessels were far more likely to be alive 14 years after treatment. Further multi-variate analysis showed that nm23 and vessel density were "the most important tumor characteristics predicting outcome."

This report, in the July 1 issue of Cancer Research, is the largest study ever completed of node-negative breast cancer patients who received no adjuvant treatment -- radiation, hormone or chemotherapy after surgery -- and have been followed long enough to fully express the malignant potential of the disease.

While 91 percent of patients with high nm23 were alive an average of 14 years after treatment, only 70 percent of those with low nm23 survived that long. The lack of angiogenesis -- growth of new blood vessels to supply the budding tumor -- was an equally valid predictor; 92 percent of patients with a low micro-vessel count (MVC) survived at least 14 years versus only 70 percent of those with a high vessel density.

"Our study provides the best clues to date about how to treat patients with node-negative breast cancers, the kind we try to find with mammography," said first author Ruth Heimann, M.D., Ph.D., professor of radiation and cellular oncology at the University of Chicago. "We hope to use these data in our efforts to devise an individualized treatment plan for each patient, to separate those who will benefit from radiation and chemotherapy after surgery from those who don't need it."

"Our inability to make that distinction, to predict who is at risk for distant spread and who is cured by surgery, has resulted in treatment that is too much for most and too little for some," adds co-author Samuel Hellman, M.D., the A.N. Pritzker Distinguished Service Professor of radiation and cellular oncology.

The study used tumor tissue from 163 patients, median age 57, treated at the University of Chicago Hospitals between 1927 and 1987 with mastectomy alone. These patients received no additional radiation, hormone or chemotherapy. Most had fairly small tumors, three centimeters or less, and no lymph node involvement. They were followed for an average of 14 years, some as long as 36 years.

The researchers found that low MVC -- few new capillaries -- was associated with excellent prognosis. High MVC, they note, "appears necessary but not sufficient for metastasis to occur."

Unfortunately, the growth of new blood vessels tends to occur quite early for most cancers; even small tumors found via mammogram frequently have a high MVC. However, patients with high MVC combined with high protective levels of nm23 also do quite well, 90 percent surviving 14 years.

The study also provides insights into the progression of breast cancers, suggesting that angiogenesis and metastasis are two separate and usually sequential events.

Decreased levels -- or mutant, nonfunctional versions -- of nm23 seem to appear somewhat later than angiogenesis. Loss of nm23 appears to be a crucial second event that must occur before the cancer can spread to distant sites.

While these markers are useful, they do not tell the whole story, insist the authors, since even for those with both high angiogenesis and non-functioning nm23 about 70 percent survive. This indicates that there are other as yet unidentified critical changes needed for tumor spread.

"Those patients with high MVC and low nm23 would be advised to have both radiation and chemotherapy following surgery," said Hellman. But for patients without a lot of tumor vessels, or even those who have some angiogenesis but still protective high nm23 levels, it might be quite reasonable to skip adjuvant chemotherapy and avoid its costs, inconvenience and discomfort. Finding better and better markers of who needs more therapy is a big step toward more rational treatment decisions."

Since breast cancer deaths result not from the original tumor but from its dissemination to distant sites, preventing metastasis, even for patients with limited risk, is a fundamental aspect of treatment, agree the authors. But "a worthwhile secondary goal is avoiding either unnecessary or insufficient treatment," notes Heimann, "and these markers, even when measured in archival, paraffin-embedded tissue, appear to provide excellent clues about who does and who doesn't need more therapy."
-end-


University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.